These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 20844209

  • 1. In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.
    Chong HS, Dagg R, Malik R, Chen S, Carter D.
    J Clin Microbiol; 2010 Nov; 48(11):4115-20. PubMed ID: 20844209
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
    Carvajal SK, Melendres J, Escandón P, Firacative C.
    Microbiol Spectr; 2023 Aug 17; 11(4):e0140323. PubMed ID: 37341584
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Molecular epidemiology and antifungal susceptibility profiles of clinical Cryptococcus neoformans/Cryptococcus gattii species complex.
    Bandalizadeh Z, Shokohi T, Badali H, Abastabar M, Babamahmoudi F, Davoodi L, Mardani M, Javanian M, Cheraghmakani H, Sepidgar AA, Badiee P, Khodavaisy S, Afshari SAK, Ahmadikia K, Seyedmousavi S.
    J Med Microbiol; 2020 Jan 17; 69(1):72-81. PubMed ID: 31750814
    [Abstract] [Full Text] [Related]

  • 10. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
    Grizante Barião PH, Tonani L, Cocio TA, Martinez R, Nascimento É, von Zeska Kress MR.
    Mycoses; 2020 Dec 17; 63(12):1341-1351. PubMed ID: 32869413
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of antifungal combination against Cryptococcus spp.
    Reichert-Lima F, Busso-Lopes AF, Lyra L, Peron IH, Taguchi H, Mikami Y, Kamei K, Moretti ML, Schreiber AZ.
    Mycoses; 2016 Sep 17; 59(9):585-93. PubMed ID: 27135278
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E, Vitali LH, Kress MRVZ, Martinez R.
    Rev Inst Med Trop Sao Paulo; 2017 Sep 17; 59():e49. PubMed ID: 28793019
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.
    Basso LR, Gast CE, Bruzual I, Wong B.
    J Antimicrob Chemother; 2015 May 17; 70(5):1396-407. PubMed ID: 25630649
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.